GRFS
Price
$9.08
Change
-$0.06 (-0.66%)
Updated
Jul 3 closing price
Capitalization
5.48B
23 days until earnings call
PFE
Price
$25.38
Change
+$0.06 (+0.24%)
Updated
Jul 3 closing price
Capitalization
157.14B
30 days until earnings call
Interact to see
Advertisement

GRFS vs PFE

Header iconGRFS vs PFE Comparison
Open Charts GRFS vs PFEBanner chart's image
Grifols SA
Price$9.08
Change-$0.06 (-0.66%)
Volume$191.16K
Capitalization5.48B
Pfizer
Price$25.38
Change+$0.06 (+0.24%)
Volume$27.1M
Capitalization157.14B
GRFS vs PFE Comparison Chart in %
Loading...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
GRFS vs. PFE commentary
Jul 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is GRFS is a Hold and PFE is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 06, 2025
Stock price -- (GRFS: $9.08 vs. PFE: $25.38)
Brand notoriety: GRFS: Not notable vs. PFE: Notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: GRFS: 27% vs. PFE: 64%
Market capitalization -- GRFS: $5.48B vs. PFE: $157.14B
GRFS [@Pharmaceuticals: Major] is valued at $5.48B. PFE’s [@Pharmaceuticals: Major] market capitalization is $157.14B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $739.66B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $86.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

GRFS’s FA Score shows that 1 FA rating(s) are green whilePFE’s FA Score has 1 green FA rating(s).

  • GRFS’s FA Score: 1 green, 4 red.
  • PFE’s FA Score: 1 green, 4 red.
According to our system of comparison, GRFS is a better buy in the long-term than PFE.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

GRFS’s TA Score shows that 4 TA indicator(s) are bullish while PFE’s TA Score has 6 bullish TA indicator(s).

  • GRFS’s TA Score: 4 bullish, 5 bearish.
  • PFE’s TA Score: 6 bullish, 4 bearish.
According to our system of comparison, PFE is a better buy in the short-term than GRFS.

Price Growth

GRFS (@Pharmaceuticals: Major) experienced а +3.42% price change this week, while PFE (@Pharmaceuticals: Major) price change was +4.70% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +1.13%. For the same industry, the average monthly price growth was +2.56%, and the average quarterly price growth was +9.33%.

Reported Earning Dates

GRFS is expected to report earnings on Nov 06, 2025.

PFE is expected to report earnings on Nov 04, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+1.13% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PFE($157B) has a higher market cap than GRFS($5.48B). PFE has higher P/E ratio than GRFS: PFE (74.92) vs GRFS (68.68). GRFS YTD gains are higher at: 22.043 vs. PFE (-0.898). PFE has higher annual earnings (EBITDA): 9.56B vs. GRFS (640M). PFE has more cash in the bank: 12.7B vs. GRFS (544M). GRFS has less debt than PFE: GRFS (11.1B) vs PFE (70.8B). PFE has higher revenues than GRFS: PFE (58.5B) vs GRFS (6.54B).
GRFSPFEGRFS / PFE
Capitalization5.48B157B3%
EBITDA640M9.56B7%
Gain YTD22.043-0.898-2,455%
P/E Ratio68.6874.9292%
Revenue6.54B58.5B11%
Total Cash544M12.7B4%
Total Debt11.1B70.8B16%
FUNDAMENTALS RATINGS
GRFS vs PFE: Fundamental Ratings
GRFS
PFE
OUTLOOK RATING
1..100
5050
VALUATION
overvalued / fair valued / undervalued
1..100
6
Undervalued
4
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
8674
PRICE GROWTH RATING
1..100
4251
P/E GROWTH RATING
1..100
9696
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PFE's Valuation (4) in the Pharmaceuticals Major industry is in the same range as GRFS (6). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

PFE's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as GRFS (100). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

PFE's SMR Rating (74) in the Pharmaceuticals Major industry is in the same range as GRFS (86). This means that PFE’s stock grew similarly to GRFS’s over the last 12 months.

GRFS's Price Growth Rating (42) in the Pharmaceuticals Major industry is in the same range as PFE (51). This means that GRFS’s stock grew similarly to PFE’s over the last 12 months.

GRFS's P/E Growth Rating (96) in the Pharmaceuticals Major industry is in the same range as PFE (96). This means that GRFS’s stock grew similarly to PFE’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
GRFSPFE
RSI
ODDS (%)
Bearish Trend 3 days ago
69%
Bearish Trend 3 days ago
55%
Stochastic
ODDS (%)
Bearish Trend 3 days ago
65%
Bearish Trend 3 days ago
51%
Momentum
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 3 days ago
55%
MACD
ODDS (%)
Bearish Trend 3 days ago
71%
Bullish Trend 3 days ago
48%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
57%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
51%
Advances
ODDS (%)
Bullish Trend 6 days ago
72%
Bullish Trend 3 days ago
56%
Declines
ODDS (%)
Bearish Trend 18 days ago
75%
Bearish Trend 9 days ago
60%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
78%
Bearish Trend 3 days ago
57%
Aroon
ODDS (%)
Bullish Trend 3 days ago
73%
Bullish Trend 3 days ago
53%
View a ticker or compare two or three
Interact to see
Advertisement
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PFE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
MFUS54.030.35
+0.65%
PIMCO RAFI Dyn Multi-Factor US Eq ETF
FMET34.130.22
+0.65%
Fidelity Metaverse ETF
MOAT96.860.29
+0.30%
VanEck Morningstar Wide Moat ETF
AGGS40.95N/A
N/A
Harbor Disciplined Bond ETF
BOE11.51-0.01
-0.09%
BlackRock Enhanced Global Dividend Trust

GRFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
-0.66%
GIKLY - GRFS
68%
Closely correlated
N/A
GIFOF - GRFS
37%
Loosely correlated
N/A
BIIB - GRFS
30%
Poorly correlated
-0.24%
PFE - GRFS
28%
Poorly correlated
+0.24%
GILD - GRFS
26%
Poorly correlated
+0.22%
More

PFE and

Correlation & Price change

A.I.dvisor indicates that over the last year, PFE has been loosely correlated with GSK. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if PFE jumps, then GSK could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PFE
1D Price
Change %
PFE100%
+0.24%
GSK - PFE
60%
Loosely correlated
-0.86%
AMGN - PFE
58%
Loosely correlated
+0.47%
ABBV - PFE
55%
Loosely correlated
-0.77%
NVS - PFE
55%
Loosely correlated
-1.54%
BMY - PFE
52%
Loosely correlated
-0.19%
More